Opinion|Videos|December 3, 2024
Bispecifics in R/R MM: AE Management and Sequencing
Author(s)Joseph R. Mikhael, MD
Panelist discusses how every drug oncologists use comes with adverse events (AEs), and with bispecifics they are seeing a similar AE profile to that seen in CAR T-cell therapy. There are 3 major AEs: cytokine release syndrome, neurological toxicity, and infections. To manage AEs, oncologists are now monitoring patients more intensely as well as engaging with the patient’s family to provide updates on the status of the patient.
Advertisement
Episodes in this series
Video content above is prompted by the following
- What AEs are you seeing in practice with bispecifics?
- What are some strategies used to manage them?
- What is your current approach to sequencing bispecifics (BCMA vs non-BCMA bispecific, CAR T vs bispecifics)?
- What insights can you share for fellow oncologists regarding sequencing?
Advertisement
Related to this article
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.
William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
5